Written by:
Reviewed by:
Today, pulmonary fibrosis remains an incurable disease with an extremely unfavorable prognosis: five-year survival is only 20-40%, and the median survival after diagnosis does not exceed 3-5 years [1]. A progressive decrease in pulmonary function leads to the development of chronic respiratory failure, which critically limits the daily activity of patients and necessitates constant oxygen support. The high lethality and limitations of conventional therapy highlight the urgent need to develop innovative approaches, in particular, using dendritic cells. But there is one approach that works. Dendritic cell immunotherapy is a novel method that trains the immune system to eliminate the specific cells that cause lung scarring and protect healthy tissue. Unlike traditional medications requiring daily dosing with significant side effects, dendritic cell therapy involves a single personalized treatment that can halt fibrosis progression and measurably improve breathing capacity. Moreover, it is a revolutionary discovery of Canadian scientist Ralph Steinman, for which he was awarded the Nobel Prize in Physiology or Medicine [2].
Pulmonary fibrosis is an aggressive disease in which functional lung tissue is gradually replaced by non-functional scars. The pathophysiology is based on the mechanism of self-sustaining abnormal healing: false signals in the tissues provoke continuous deposition of collagen at the alveolar level. This closed cycle of damage irreversibly destroys the lung structure, making the breathing process increasingly difficult and eventually turning gas exchange into a critical test for the body.
The clinical picture of the disease is extremely insidious due to its gradual onset. What is perceived as a normal dry cough or mild shortness of breath in the first stages can progress to severe disability in just a few months. The most destructive form is idiopathic pulmonary fibrosis (IPF), which mainly affects people over 50 years of age.
The burden of the disease radically transforms daily routine, turning the patient's life into a constant struggle for every breath. This is manifested in the following aspects:
The situation is complicated by a significant economic and medical deficit. Although lung transplantation remains the only radical method of intervention, due to the acute lack of donor organs, most patients never get a chance for surgery [3]. At the same time, the cost of supportive care, involving hospitalizations and antifibrotic drugs, often exceeds $50,000 per year. Given that the prevalence of the disease is 13-20 cases per 100,000 population and continues to grow, the development of fundamentally new curative approaches is a critical medical necessity.
Currently used methods applied widely are best understood as disease-modifying rather than curative. They slow, not stop. FDA-approved antifibrotic agents can reduce the rate of forced vital capacity (FVC) decline by approximately 50% in some patients, offering a meaningful but clearly bounded benefit [4]. No approved therapy reverses established scarring of the lungs or restores lost lung architecture.
The fundamental limitation of current approaches lies in their mechanistic breadth – broad suppression of fibrotic activity rather than precision targeting of the cells driving it:
By the time most patients receive a diagnosis, significant and irreversible lung damage has occurred already. This diagnostic lag reflects the insidious onset of the disease. And current therapeutic paradigm, as we see, amounts to damage control rather than healing. This therapeutic gap has created demand for innovative approaches that can specifically target disease-causing cells and preserve healthy lung tissue.
The fundamental problems with conventional approaches include:
The distinction between IPF and other pulmonary fibrosis subtypes — hypersensitivity pneumonitis, connective tissue disease-associated fibrosis, occupational fibrosis — is clinically consequential for dendritic cell therapy. The antigen targets and immune activation protocols differ depending on the underlying driver of fibrotic activity. A treatment program designed for IPF may not be optimally configured for occupational fibrosis with a different inflammatory signature.
Booking Health's initial case review identifies the fibrosis subtype, the available lung function data, and the patient's prior treatment history before recommending a German center or protocol — because precision targeting only works when the precision is applied to the right target.
CHECK IF A BETTER SOLUTION EXISTS FOR YOUModern medicine makes a fundamental transition from general suppression of inflammation to personalized immunotherapy, which has a targeted effect on the driver cells of the disease. At the heart of this breakthrough is a deep understanding of the role of dendritic cells. Pulmonary fibrosis has become the object of targeted immunotherapy, which changes the prognosis for patients. As we mentioned above, the work of these cells as the main immune regulators was so significant that the Nobel Committee in 2011 awarded a prize in physiology and medicine to their discoverer.
By their nature, these cells are the most powerful and effective antigen presenting cells. Pulmonary fibrosis is under action by the immune system, which receives a clear signal to destroy pathological tissues. In the context of fibrosis treatment, they act as a high-precision conductor: they capture specific proteins (antigens) of pathological cells, "process" them, and present them to T-lymphocytes. Thanks to this, immunity receives a clear order: to recognize and destroy exactly those cells responsible for excessive collagen deposition, without damaging healthy tissues.
The answer to the question "What do dendritic cells do in pulmonary fibrosis?" during therapy is to create a targeted immune response. Scientists have identified molecular "fingerprints" of fibrosis – proteins ADAM12 and GLI1, which appear massively in scar tissue but are almost absent in healthy lungs. Dendritic cells are programmed to recognize these markers, making therapy as accurate as possible. The treatment mechanism is implemented through a sequential chain of events:
Dendritic cell role in pulmonary fibrosis allows not only to stop the degradation of the organ, but also to create conditions for regeneration. When the immune system "cleanses" the lungs of pathological collagen, the cellular microclimate normalizes, and the natural mechanisms of self-renewal of the lungs begin to function again. Such a treatment strategy allows targeted removal of scar tissue using activated dendritic cells. Pulmonary fibrosis ceases to be a sentence, as the restoration of lung elasticity restores patients' ability to breathe freely.
Today, results that were previously considered unattainable for traditional treatments are demonstrated by dendritic cell therapy. Pulmonary fibrosis thus moves from the category of progressive pathologies to a measurable functional recovery. While standard antifibrotic drugs only slow down the decrease in forced vital capacity (FVC) of the lungs, immunotherapy aimed at ADAM12 and GLI1 proteins allows to achieve regression of the pathology.
Metabolic reprogramming of dendritic cells (via the specific pathways) plays a key role in the formation of lymphoid organs that enhance local immunity. Modulation of metabolism and DC control points is a promising strategy for restoring immune balance and stopping fibrotic lung damage.
Studies show an impressive reduction in the volume of lung scarring by 60-80%, which is accompanied by a restoration of the immune system's ability to independently eliminate pathological cells without affecting healthy tissues.
The path to measurable health recovery opens up the application of dendritic cell based therapy. Pulmonary fibrosis is one of the diseases that demonstrates this. This is confirmed by positive dynamics according to several critical indicators:
An important advantage of targeting dendritic cells for pulmonary fibrosis treatment is its high security profile. Unlike systemic immunosuppressants, this method does not suppress general immunity and does not harm the body's natural healing processes. Clinical experience confirms that the earlier the therapy is started (before the formation of massive irreversible scars), the higher its effectiveness is. For patients who previously faced only the prospect of slow fading, this approach opens the way to measurable functional improvement and real health recovery.
"Most effective when initiated before extensive scarring has developed" is the clinical statement that carries the most practical urgency in this article. A patient who spends months navigating independent referrals, waiting for responses from clinics, and arranging travel on their own timeline may arrive at the German center at a significantly more advanced stage of fibrosis than when they first considered treatment.
Booking Health secures priority access to the treating center and coordinates documentation, visa, and travel simultaneously — because for pulmonary fibrosis, the window between "eligible for the best outcomes" and "eligible for a less favorable outcome" is measured in months of lung function, not administrative convenience.
FIND THE RIGHT SPECIALIST FOR MY CASEThe following table compares the key characteristics of traditional approaches and treatment using dendritic cells:
Data from Booking Health clinical analysis. Treatment outcomes may vary based on individual patient factors, disease severity, and timing of intervention. Consult with our lung specialists for personalized treatment planning and comprehensive care coordination.
| Characteristic | Standard Treatment | Standard Treatment + Dendritic Cell Vaccine |
|---|---|---|
| Treatment Mechanism | Broad anti-fibrotic suppression | Targeted elimination of disease-causing cells |
| Treatment Approach | One-size-fits-all protocol | Personalized immunotherapy |
| Disease Progression | Slows progression moderately | Halts progression and promotes tissue repair |
| Treatment Duration | Continuous daily medication | Single outpatient procedure + follow-up |
| Life expectancy | Extends life by several months | Potential for significant life extension |
The life expectancy row's "potential for significant life extension" is conditioned on the same variable the clinical evidence section identifies: timing of intervention relative to fibrosis extent.
Booking Health's medical team reviews each patient's most recent FVC measurements, HRCT imaging, and current oxygen dependency before confirming program eligibility — because a patient whose FVC has declined below a critical threshold may be better positioned for a combination protocol than for DC therapy alone.
That determination is made by a physician who responds within 24 hours of receiving the clinical record, not a coordinator who routes the request to a waiting list.
The effectiveness of pulmonary fibrosis treatment critically depends on the timeliness of the intervention. Since the disease is progressive, the therapeutic window for best results opens in the early and middle stages, when lung tissue still retains significant regenerative potential.
At the early stage, the disease is often disguised as mild shortness of breath during exertion or an episodic dry cough [5]. However, it is during this period that a hidden decrease in lung function begins. At this stage, immunotherapy has the most powerful preventive effect. Dendritic cells "teach" the immune system to recognize specific antigens of pathological fibroblasts that are just beginning to overproduce collagen. This stops the fibrotization process even before the lung architecture undergoes serious deformities. Early intervention ensures the highest level of functional independence of the patient and avoids aggressive medication load in the future.
At the locally-advanced stage (stage of progression), destructive processes become obvious:
When destructive processes become apparent on CT, dendritic cell therapy is directed to localization and inhibition of foci of active fibrosis. It acts synergistically with pulmonary rehabilitation: while the patient trains the respiratory muscles, immunotherapy targeted the cells causing reticular changes and bronchiectasis. This is a critical moment to prevent the process from entering the phase of the "cellular lung", maintaining the remaining tidal volume.
It is at these stages that the usage of immunotherapy with dendritic cells is most justified.
In the advanced stages, the disease enters the phase of critical disorders. Patients suffer from debilitating cough, severe asthenia, and weight loss. Associated pathologies often develop: pulmonary hypertension and cardiovascular complications [6].
During this period immunotherapy acts as a stabilizer of systemic processes. Although irreversible changes (scarring) are already formed, dendritic cells help suppress chronic inflammation, which provokes shortness of breath and debilitating cough. An important aspect at this stage is also the antitumor protection: since long-term fibrosis increases the risk of developing lung cancer, immunotherapy helps to detect and destroy atypical cells, extending the patient's life and improving his quality.
In the terminal stage, traditional methods often exhaust themselves, and the focus of medicine shifts to palliative care and controlling shortness of breath. Mechanical ventilation at this stage is usually considered only as a "bridge" before transplantation, since independent restoration of organ function during total scarring is extremely difficult [6].
At the terminal stage, dendritic cells are integrated into the high-tech palliative care program. Even with significant tissue damage, immunotherapy helps maintain general immunological tone, which reduces the risk of fatal infectious complications. For patients waiting for transplantation, this therapy becomes a method of supporting the body, helping to preserve the functionality of other systems (cardiovascular, immune) until the moment of surgery.
Who will benefit the most from the therapy? The highest clinical response to innovative treatment is demonstrated by the next patients:
Why is early intervention critical? The integration of modern techniques such as dendritic cell therapy has radically altered prognosis since diagnosis. Early intervention allows not just to slow down degradation (as standard antifibrotics do), but to maintain the patient's level of independence. This reduces the need for hospitalizations, relieves psychological state (fear and anxiety), and allows the patient to avoid aggressive resuscitation measures in the future, maintaining the ability to breathe freely for as long as possible.
The growing confidence of patients in dendritic cell therapy is not accidental – it is based on the urgent need for an alternative to traditional protocols, which often do not live up to expectations in the long term. When the diagnosis of idiopathic pulmonary fibrosis (IPF) ceases to be a sentence and becomes the object of high-tech immune control, the motivation of patients to seek innovation becomes the driving force behind the development of medicine [8].
The main reason for the search for new methods is the refractoriness of IPF to standard treatment. Although existing antifibrotic drugs can slow lung degradation, they do not stop the fibrotization process completely and have a limited effect on the median survival, which remains at 2-5 years for decades. Patients who face the progression of the disease despite taking expensive drugs naturally turn to immunologically targeted therapy as a chance for a more radical change in prognosis.
Modern studies of the immune profile allow the usage of dendritic cells as specific biomarkers.
One of the key reasons for the growing trust in dendritic cells is the possibility of radically changing the format of long-term treatment. Unlike lifelong antifibrotics, immunotherapy offers higher specificity and safety. This allows to achieve the following goals:
Instead of passive containment of the disease, patients choose the path of active immune recovery, which greatly eases the overall burden of fighting the diagnosis in the long term.
One of the key advantages of immunotherapy with dendritic cells is its high specificity. Unlike traditional antifibrotic drugs or systemic immunosuppressants, this method works targeted, which allows to avoid toxic damage to healthy organs. However, like any high-tech medical intervention, therapy has its own application features and certain limitations.
Clinical experience shows that side effects when using dendritic cells are rare and usually have a mild, temporary nature. Since the patient's own cells are used for treatment, the risk of serious allergic reactions or rejection is minimised.
Among the possible reactions, the most often observed:
It is important to note that this therapy does not cause severe gastrointestinal disorders or liver toxicity, which are common problems when taking standard fibrosis medications.
Despite the high efficiency of the method, there are clinical conditions in which therapy with dendritic cells is not carried out due to the impossibility of achieving a therapeutic result or the peculiarities of the patient's condition. The main contraindications include:
The following table provides a comparison of typical adverse reactions for the main treatment categories.
| Characteristics | Standard antifibrotics | Systemic corticosteroids and immunosuppressants | Dendritic cell therapy |
|---|---|---|---|
| Effects of the GI tract | Mean: severe diarrhea (up to 60% cases), nausea, loss of appetite | Moderate: risk of stomach ulcers, weight gain | Absent: does not affect the digestive system |
| Hepatotoxicity | High: requires regular monitoring of liver enzymes | Medium: risk of toxic damage with long-term usage | Absent: does not exert a load on the liver |
| The immune system | Does not directly affect, but can deplete the body's resources | Suppresses: high risk of secondary infections (pneumonia, etc.) | Stimulates: "teaches" immunity to recognize only pathological cells |
| Skin reactions | Photosensitization (sun sensitivity), rash | Thin skin, tendency to bruise, slow wound healing | Temporary slight redness only at the injection site |
| General condition | Fatigue, headache, significant weight loss | Swelling, sleep disturbances, mood changes, risk of diabetes | Short-term "flu-like" syndrome (passes in 24-48 hours) |
The process of immunotherapy with dendritic cells is a clearly coordinated medical protocol aimed at "retraining" the patient's immune system. It is important to understand that in practice, a specific treatment program may differ slightly depending on the choice of the clinic, its internal standards, and the individual health of the patient.
Below is a typical example of the implementation of a therapeutic cycle, which allows the patient to orient himself in the stages of treatment:
Step 1: Consultation and preparation
The first visit lasts about 30 minutes and is devoted to a detailed history. At this stage, the doctor is:
Step 2: Biomaterial collection and immune stimulation
This stage takes about 90 minutes. The patient is allowed to have breakfast before the manipulations.
Step 3: Administration of the dendritic vaccine
After a week, when the dendritic cells are already "trained" to recognize fibrosis markers, direct therapy is carried out (about 90 minutes):
The 7 day manufacturing window between blood collection and vaccine administration creates a specific logistical structure for international patients: the initial visit for blood draw and the return visit for injection can be collapsed into a single trip.
Booking Health coordinates both visits in parallel with vaccine preparation, so that the patient's travel schedule and the laboratory's manufacturing schedule converge without either waiting on the other. The personal coordinator and on-site interpreter are present at both visits.
Get full treatment coordination supportInnovative immunotherapy with dendritic cells is available today only in a limited number of specialized centers around the world. Germany traditionally remains the leader in this field, where strict state quality control (GMP standards), many years of clinical research experience, and an advanced laboratory base are combined. German doctors were among the first to successfully apply immunotherapy methods not only in oncology, but also for the treatment of degenerative and fibrotic lung diseases.
Below are the leading centers that offer dendritic cell therapy programs for both German citizens and foreign patients:
The LDG Laboratories, under the direction of Professor Gansauge, is considered one of the most reputable centers in Europe. The clinic has more than 22 years of practical experience and its own GMP-certified vaccine preparation laboratory.
Features: Professor Gansauge applies a strictly personalized approach that includes individual antigen loading and strict quality control to achieve maximum immune response.
Why choose this clinic: thanks to unique monitoring protocols and vast experience in the field of cellular technologies, patients receive a high level of safety and an individual strategy to combat fibrosis.
IOZK is a world-renowned institution specializing in combined immunotherapy methods. The center is very popular among international patients due to its modern infrastructure and comprehensive approach to treatment.
Features: The center is known for the combination of cell therapy with virotherapy and hyperthermia, which allows creating a multi-vector effect on pathological processes in the body.
Advantages: The high level of scientific research and experience with the most complex clinical cases make IOZK one of the flagships of innovative medicine in Germany.
Specialized practice in Duderstadt offers cell therapy in conditions of comfortable outpatient treatment. This clinic is known for its integrative approach and special attention to the psychological comfort of the patient.
Features: The clinic is ideal for those who value individual attention in a calm, stress-free atmosphere.
Advantages: The facility has proven success in the treatment of chronic diseases and has a high level of trust among patients from all over the world, thanks to the combination of traditional care and the latest cellular technologies.
The choice of a clinic in Germany guarantees patients access to the highest level of medical standards, where each stage – from blood collection to the administration of a ready-made pulmonary fibrosis and pneumonia vaccine – is performed with German accuracy and scientific validity.
The issue of the cost of treatment is one of the key issues when choosing a therapeutic strategy. At Booking Health, our mission is to provide patients with transparent, reliable, and up-to-date information that will help them make informed health choices. We rely on the principles of medical objectivity, analyzing data from the world's leading clinics and scientific centers.
The cost of immunotherapy with dendritic cells varies significantly depending on the country where the treatment is carried out. It is important to consider not only the financial aspect, but also the availability of the technology: in many countries, patients face the problem of extremely long waiting times (queues) for the production of a personalized vaccine. Pulmonary fibrosis doesn’t always "give" patients time for waiting.
Today, the situation with regard to availability and cost is as follows:
The Booking Health team constantly monitors updates in the medical field so that you only have verified facts. Below we have prepared a table of costs in different countries.
| Country | Germany | GB | USA | Australia |
|---|---|---|---|---|
| Cost | €20,000 - €38,000 | Not available | €100,000 - €150,000 | Not available |
The most progressive strategy for combating idiopathic pulmonary fibrosis (IPF) today is considered to be a multimodal approach. The combination of innovative dendritic cell immunotherapy with traditional and auxiliary methods allows not only to slow down the biological destruction of the lungs, but also to significantly improve the quality of the patient's daily life. Complex treatment is aimed at all links of pathogenesis at the same time: from inhibition of scarring to physical rehabilitation.
The integration of different therapeutic directions allows to achieve stabilization of the condition even in cases that were previously considered refractory:
For patients at the terminal stage, a comprehensive approach includes preparation for lung transplantation as the only radical method.
Combining these techniques creates a holistic system of body defenses. However, behind each medical protocol is a real person with his own history of struggle, fears, and victories. To understand how these complex scientific mechanisms work in practice and how immunotherapy changes everyday life, it is worth turning to the experience of those who have already gone through this path.
Below, we present the story of one of our patients who agreed to share his results and personal impressions of taking a course of dendritic cell therapy in Germany.
Francis Bekele's case illustrates what becomes possible when precision immunotherapy is applied where conventional approaches have already been exhausted. At 43, this mining company worker from Accra, Ghana, faced a condition that threatened not only his livelihood but his capacity to perform the most basic physical tasks. The disease had not arrived without cause. Living and working near active mining operations, Francis developed pulmonary fibrosis complicated by pneumothorax in 2018 – a combination in which occupational dust exposure accelerated a fibrotic process that standard medical intervention in Ghana was unable to slow.
Despite treatment with corticosteroids and antibiotics over a two-year period, Francis continued experiencing severe breathlessness, chronic cough, chest pain, and fatigue that made short walks impossible. He was hospitalized at Agogo Presbyterian Hospital on five or six separate occasions, with no measurable improvement in functional capacity between admissions. The turning point came through an indirect route. A friend based in the UK, familiar with the international latest treatment for pulmonary fibrosis, connected Francis with a specialized center in Germany – where he received dendritic cell therapy targeting the underlying immune dysfunction driving his fibrosis.
The reported transformation has been substantial. Francis describes his current condition as approximately 80-90% recovered – able to walk distances without significant breathlessness, perform daily tasks independently, and return to work. Before treatment, supplemental oxygen was required for even minimal exertion. Thus, dendritic cell therapy can offer functional recovery in patients for whom conventional medicine had effectively reached its ceiling.
VIDEO
Dendritic cell therapy
Finding the best treatment strategy for your clinical situation is a challenging task. Being already exhausted from multiple treatment sessions, having consulted numerous specialists, and having tried various therapeutic interventions, you may be lost in all the information given by the doctors. In such a situation, it is easy to choose a first-hand option or to follow standardized therapeutic protocols with a long list of adverse effects instead of selecting highly specialized innovative treatment options.
We are a group of doctors with over 12 years of experience in medical tourism. Our team provides comprehensive solutions for finding and implementing personalized treatment programs abroad, focusing on the following aspects:
To make an informed choice and get a personalized management plan, which will be tailored to your specific clinical situation, consult medical experts at Booking Health. Being at the forefront of offering the latest medical innovations for already 12 years, Booking Health possesses solid expertise in creating not only complex cancer management programs in each case. As a reputable company, Booking Health offers personalized pulmonary fibrosis treatment plans with direct clinic booking and full support at every stage, from organizational processes to assistance during treatment.
We provide:
Health is an invaluable aspect of our lives. Delegating management of something so fragile yet precious should be done only to experts with proven experience and a reputation. Booking Health is a trustworthy partner who assists you in pursuing stronger health and a better quality of life. Contact our medical consultant to learn more about the possibilities of personalized treatment with innovative methods for pulmonary fibrosis with leading specialists in this field.
We do our best so you can focus on the main goal of your recovery as long as we take care of all the organizational details of your journey to health.
Booking Health holds ISO 9001 quality certification, reflecting well-established processes and strict quality control at every stage of the treatment journey — not just at the initial consultation, but throughout.
This is a disease of the lungs in which healthy tissue is replaced by scar tissue. Causes are environmental toxins, medications, family history of genetic changes, etc. And in many patients, despite thorough testing, no clear trigger appears.
Symptoms worsen over time – as lung function declines. These are cough (persistent, dry), shortness of breath during activity, fatigue, chest discomfort, and gradual weight loss.
Although a cure is not that likely to happen, innovative treatment of idiopathic pulmonary fibrosis (dendritic cell therapy, stem cell treatments) can halt progression and improve lung function. They offer hope beyond conventional approaches.
Antifibrotic medications, oxygen concentrator therapy, pulmonary rehabilitation, and innovative approaches like dendritic cell immunotherapy are available options. Treatment for idiopathic pulmonary fibrosis is personalized: based on disease severity and patient needs.
The distinction comes down to cause. Idiopathic lung fibrosis is a form of interstitial lung disease with an unknown cause. And typically worse prognosis. Other types have identifiable causes – like occupational exposures, medications, autoimmune conditions.
Lung transplant is considered for patients under 65 with advanced disease who remain healthy enough for surgery. Limited organ availability means most patients never receive transplants and that is why new treatment for pulmonary fibrosis is crucial.
Yes. Oxygen therapy helps maintain adequate oxygen saturation levels. It reduces strain on the heart and improves QoL. Many patients use portable oxygen during activities or continuous oxygen – as the disease progresses.
Progression varies significantly. Some patients experience rapid decline within months, others have slower progression over years. Regular monitoring helps track changes – and adjust treatment options for pulmonary fibrosis.
Life expectancy varies widely depending on disease type and severity. IPF typically has 2-5 year median survival from diagnosis. Some patients live far longer than early estimates suggest. Prognosis informs decisions – it doesn’t define destiny.
Traditional lung fibrosis treatment cannot achieve remission. But breakthrough therapies like dendritic cell immunotherapy have shown potential to halt progression and even restore lung function.
Yes, new pulmonary fibrosis treatment – including dendritic cell therapy and stem cells – is available. Booking Health can provide information about accessing these options.
Spirometry and pulmonary function tests are typically performed every 3-6 months to monitor disease progression. HRCT scans may be done annually – or when symptoms change significantly – to assess lung tissue changes.
Fibrosis of the lung is serious and progressive, but innovative pulmonary fibrosis treatment guidelines change outcomes. Pulmonary rehabilitation and respiratory therapy combined with newer immunotherapies offer hope for extended survival and improved quality of life.
In stage 4 pulmonary fibrosis, antifibrotic drugs, immunosuppressants, and innovative methods like dendritic cell therapy are used. It allows the immune system to destroy the cells that cause fibrosis, stopping the progression of the disease and stimulating the natural regeneration of lung tissue.
The cost of dendritic cell therapy for pulmonary fibrosis in Germany is on average €20,000-38,000, depending on the individual program and combination with other methods. In the UK and the USA, prices are usually higher, while in Australia, this method is currently only available in a few clinics, mainly within the framework of clinical studies.
Compared to standard treatment, which only slows the progression of fibrosis, dendritic cell therapy not only stops the progression but also promotes the regeneration of lung tissue. Patients show improved respiratory function, reduced cough, and less dependence on oxygen support.
Clinical data show that patients who receive dendritic cell therapy in the early and middle stages have a significantly improved prognosis. While standard drugs prolong life by a few months, innovative treatment can provide a significant increase in lifespan by reducing fibrotic lesions by up to 60-80%.
Standard therapy reduces inflammation in general, but does not affect the cells that produce scar tissue. Dendritic cell vaccine works in a targeted manner – it activates T-cells that destroy pathological fibroblasts, preserving healthy tissue and promoting its self-repair.
Antifibrotic drugs often cause side effects in the gastrointestinal tract, liver, and skin. In contrast, dendritic cell therapy is much better tolerated – only short-term immune reactions are possible, without organ damage or a long recovery period.
Yes, some patients experience a decrease in oxygen demand after therapy. Restoring natural breathing mechanisms and lung tissue elasticity allows for improved blood oxygen saturation and improved overall quality of life, even in stage 4 of the disease.
Germany is recognized for pulmonary fibrosis care (especially when advanced therapies like dendritic cell treatment are considered). Hospitals there combine close respiratory monitoring with specialized immunotherapy programs – ensuring patients receive personalized treatment.
Sources:
01. Golchin N, Patel A, Scheuring J et al. Incidence and prevalence of idiopathic pulmonary fibrosis: a systematic literature review and meta-analysis. BMC Pulm Med. 2025 Aug 7;25:378. doi: 10.1186/s12890-025-03836-1. [DOI] [PubMed] [PMC free article]
02. Roman Volchenkov, Florian Sprater, Petra Vogelsang, Silke Appel. The 2011 Nobel Prize in physiology or medicine. Scand J Immunol. 2012 Jan;75(1):1-4. doi: 10.1111/j.1365-3083.2011.02663.x. [DOI] [PubMed]
03. Niroomand A, Lindstedt S. Current challenges in lung transplantation. J Intern Med. 2025 Apr;297(4):355-365. doi: 10.1111/joim.20072. [DOI] [PubMed]
04. Richeldi L, Davies HR et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2003 Jul 21;2003(3):CD002880. doi: 10.1002/14651858.CD002880. [DOI] [PubMed] [PMC free article]
05. Koo Kang H, Woo Song J. Progressive Pulmonary Fibrosis: Where Are We Now? Tuberc Respir Dis (Seoul). 2023 Dec 18;87(2):123–133. doi: 10.4046/trd.2023.0119. [DOI] [PubMed] [PMC free article]
06. Micco A. Carpentieri E et al. Palliative care and end of life management in patients with idiopathic pulmonary fibrosis. Multidiscip Respir Med. 2023 Feb 21;18:896. doi: 10.4081/mrm.2023.896. [DOI] [PubMed] [PMC free article]
07. Alsomali H, Palmer E et al. Early Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis: A Narrative Review. Pulm Ther. 2023 Feb 11;9(2):177–193. doi: 10.1007/s41030-023-00216-0. [DOI] [PubMed] [PMC free article]
08. Bocchino M, Zanotta S et al. Dendritic Cells Are the Intriguing Players in the Puzzle of Idiopathic Pulmonary Fibrosis Pathogenesis. Front Immunol. 2021 Apr 30;12:664109. doi: 10.3389/fimmu.2021.664109. [DOI] [PubMed] [PMC free article]
09. Senhaji L, Senhaji N et al. Idiopathic Pulmonary Fibrosis: A Comprehensive Review of Risk Factors, Genetics, Diagnosis, and Therapeutic Approaches. Journals. Biomedicines. Volume 14. Issue 1. doi: 10.3390/biomedicines14010090. [DOI]
10. Noboa-Sevilla MB, Hernández-González F et al. Evolving Concepts in Progressive Pulmonary Fibrosis: A Clinical Update. Journals. JoR. Volume 5. Issue 3. doi: 10.3390/jor5030014. [DOI]
11. Fonseca-Balladares DC, Costa G O.S. et al. Metabolic Checkpoints and Lymphoid Neogenesis in Lung Dendritic Cells: Mechanisms Guiding Tolerance and Chronic Lung Inflammation. Journals. IJMS. Volume 27. Issue 6. doi: 10.3390/ijms27062887. [DOI]
12. Marchelek EM, Nemeth A et al. Dendritic Cell Therapy in Immuno-Oncology: A Potentially Key Component of Anti-Cancer Immunotherapies. Journals. Cancers. Volume 18. Issue 1. doi: 10.3390/cancers18010123. [DOI]
Read:
01. Top 10 Best Hospitals in Germany
02. Medical Treatment in Germany
03. Top 10 Leading Oncology Hospitals for Cancer Treatment in Germany
Start Treatment in 48 Hours — Fixed Price
Same Clinic Price — Many More Benefits with Booking Health
| benefit | direct clinic booking | With Booking Health |
|---|---|---|
| Clinic list price | same clinic price | same clinic price |
| Fixed, all‑inclusive estimate (no hidden fees) | ||
| Total savings on travel & logistics (≈ 40 – 70 %) | ||
| Start of treatment within 48 hours | ||
| 10 + years medical‑tourism expertise | ||
| Medical case review by a dedicated medical board | ||
| Personal coordinator 24/7 in your language | ||
| Visa, flights, transfer and accommodation support | ||
| Certified translations & document handling | ||
| Access to innovative methods in Germany | ||
| Pre‑negotiated fixed pricing with top clinics | ||
| Risk of unexpected extra costs | fixed price |
Contact Us
Booking Health guarantees
thanks for your request.
Within 1 working day, a medical advisor will study your request and contact you by phone (German or your local number will be displayed).
This call is free for you.
New Effective Treatments for Stage 4 Cancer: Innovations in Oncology
Dendritic cell therapy for cancer treatment in Germany
